Magnesium lithospermate B mediates anti-inflammation targeting activator protein-1 and nuclear factor-kappa B signaling pathways in human peripheral T lymphocytes

International Immunopharmacology

Volumn 13, Issue 3, 2012, Pages 354-361

  Cheng, Cheng Chung ^a   Yang, Shih Ping ^a   Lin, Wei Shiang ^a   Ho, Ling Jun ^b   Lai, Jenn Haung ^a   Cheng, Shu Meng ^a   Lin, Wen Yu ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Activator protein 1; c Jun N terminal kinase; Magnesium lithospermate B; Nuclear factor kappa B; T lymphocytes

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; IONOMYCIN; MAGNESIUM LITHOSPERMATE; MITOGEN ACTIVATED PROTEIN KINASE 10; OCTAMER TRANSCRIPTION FACTOR 1; PHORBOL MYRISTATE; PROTEIN P50; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CD25+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DNA BINDING; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG SYNTHESIS; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOPHARMACOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; DNA; DRUGS, CHINESE HERBAL; HUMANS; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; OCTAMER TRANSCRIPTION FACTOR-1; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1;

EID: 84861470344     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.04.011     Document Type: Article

References (72)

1. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70: 733-7.
2. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-8. (Pubitemid 40923403)
3. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986;6:131-8. (Pubitemid 16024121)
4. Paoletti R, Gotto Jr AM, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004;109:III20-6. (Pubitemid 38786439)
5. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation 2003;108:1917-23. (Pubitemid 37296533)
6. Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci 2009;338:310-8.
7. Wierzbicki AS. Hot and bothered: C-reactive protein, inflammation and atherosclerosis. Int J Clin Pract 2009;63:1550-3.
8. Schulze Horn C, Ilg R, Sander K, Bickel H, Briesenick C, Hemmer B, et al. High-sensitivity C-reactive protein at different stages of atherosclerosis: results of the INVADE study. J Neurol 2009;256:783-91.
9. Jonasson L, Holm J, Skalli O, Gabbiani G, Hansson GK. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985;76:125-31. (Pubitemid 15240426)
10. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
11. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000;102:2919-22.
12. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995;92:3893-7.
13. van Puijvelde GH, van Wanrooij EJ, Hauer AD, de Vos P, van Berkel TJ, Kuiper J. Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb Haemost 2009;102:223-30.
14. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33-43. (Pubitemid 29292698)
15. Hansson GK, Jonasson L. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2009;29:1714-7.
16. Fish JM, Welchons DR, Kim YS, Lee SH, Ho WK, Antzelevitch C. Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006;113:1393-400. (Pubitemid 43739435)
17. Ji XY, Tan BK, Zhu YZ. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 2000;21:1089-94. (Pubitemid 32012715)
18. Chen KJ. Certain progress in the treatment of coronary heart disease with traditional medicinal plants in China. Am J Chin Med 1981;9:193-6.
19. Cheng TO. Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease. Int J Cardiol 2006;113:437-8. (Pubitemid 44708326)
20. Min LQ, Dang LY, Ma WY. Clinical study on effect and therapeutical mechanism of composite Salvia injection on acute cerebral infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002;22:353-5.
21. Kang DG, Yun YG, Ryoo JH, Lee HS. Anti-hypertensive effect of water extract of danshen on renovascular hypertension through inhibition of the renin angiotensin system. Am J Chin Med 2002;30:87-93. (Pubitemid 41758924)
22. Qiu ZX, Ma HJ, Wang DF. Observation on effect of compound danshen droplet-pill combined with trimetazidine in treating senile unstable angina pectoris. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005;25:787-9.
23. Lam FY, Ng SC, Cheung JH, Yeung JH. Mechanisms of the vasorelaxant effect of Danshen (Salvia miltiorrhiza) in rat knee joints. J Ethnopharmacol 2006;104: 336-44. (Pubitemid 43356645)
24. Wojcikowski K, Johnson DW, Gobe G. Medicinal herbal extracts-renal friend or foe? Part two: herbal extracts with potential renal benefits. Nephrology (Carlton) 2004;9:400-5. (Pubitemid 40115967)
25. Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol 2007;121:9-22. (Pubitemid 47287779)
26. Wu XJ, Wang YP, Wang W, Sun WK, Xu YM, Xuan LJ. Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B. Acta Pharmacol Sin 2000;21:855-8.
27. Jung M, Lee HC, Ahn CW, Park W, Choi S, Kim H, et al. Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Chem Pharm Bull (Tokyo) 2002;50:1135-6. (Pubitemid 41702083)
28. Yokozawa T, Chung HY, Dong E, Oura H. Confirmation that magnesium lithospermate B has a hydroxyl radical-scavenging action. Exp Toxicol Pathol 1995;47:341-4.
29. Yokozawa T, Dong E, Oura H, Kashiwagi H, Nonaka G, Nishioka I. Magnesium lithospermate B suppresses the increase of active oxygen in rats after subtotal nephrectomy. Nephron 1997;75:88-93. (Pubitemid 27052943)
30. Fung KP, Zeng LH, Wu J, Wong HN, Lee CM, Hon PM, et al. Demonstration of the myocardial salvage effect of lithospermic acid B isolated from the aqueous extract of Salvia miltiorrhiza. Life Sci 1993;52:PL239-44.
31. +-ATPase and neuroprotective effects against ischemic stroke. Acta Pharmacol Sin 2007;28:609-15.
32. Hur KY, Seo HJ, Kang ES, Kim SH, Song S, Kim EH, et al. Therapeutic effect of magnesium lithospermate B on neointimal formation after balloon-induced vascular injury. Eur J Pharmacol 2008;586:226-33.
33. Tanaka M, Asahi Y, Masuda S, Ota T. Binding position of phenylbutazone with bovine serum albumin determined by measuring nuclear magnetic resonance relaxation time. Chem Pharm Bull (Tokyo) 1989;37:3177-80. (Pubitemid 20126514)
34. Lai JH, Ho LJ, Lu KC, Chang DM, Shaio MF, Han SH. Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 2001;166:6914-24.
35. Lai JH, Ho LJ, Kwan CY, Chang DM, Lee TC. Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: potential immunosuppressants in transplantation immunology. Transplantation 1999;68: 1383-92.
36. Lai JH, Horvath G, Subleski J, Bruder J, Ghosh P, Tan TH. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol Cell Biol 1995;15:4260-71.
37. Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM. Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 1985;313:318-20. (Pubitemid 15151988)
38. Paik YH, Yoon YJ, Lee HC, Jung MK, Kang SH, Chung SI, et al. Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. Exp Mol Med 2011;43:341-9.
39. Wigren M, Kolbus D, Duner P, Ljungcrantz I, Soderberg I, Bjorkbacka H, et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med 2010;269:546-56.
40. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006;12:178-80. (Pubitemid 43214743)
41. Zhang W, Xing SS, Sun XL, Xing QC. Overexpression of activated nuclear factor-kappa B in aorta of patients with coronary atherosclerosis. Clin Cardiol 2009;32:E42-7.
42. Woodside DG, McIntyre BW. Inhibition of CD28/CD3-mediated costimulation of naive and memory human T lymphocytes by intracellular incorporation of polyclonal antibodies specific for the activator protein-1 transcriptional complex. J Immunol 1998;161:649-58. (Pubitemid 28323526)
43. Thum T, Borlak J. LOX-1 receptor blockade abrogates oxLDL-induced oxidative DNA damage and prevents activation of the transcriptional repressor Oct-1 in human coronary arterial endothelium. J Biol Chem 2008;283:19456-64.
44. Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) transcriptional regulation by Oct-1 in human endothelial cells: implications for atherosclerosis. Biochem J 2006;393:255-65. (Pubitemid 43049322)
45. Elkind MS, Rundek T, Sciacca RR, Ramas R, Chen HJ, Boden-Albala B, et al. Interleukin-2 levels are associated with carotid artery intima-media thickness. Atherosclerosis 2005;180:181-7.
46. Simon AD, Yazdani S, Wang W, Schwartz A, Rabbani LE. Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease. Clin Cardiol 2001;24:253-6. (Pubitemid 32187074)
47. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991;11:1223-30.
48. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996;157: 4159-65. (Pubitemid 126449330)
49. Boquist S, Ruotolo G, Tang R, Bjorkegren J, Bond MG, de Faire U, et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 1999;100: 723-8. (Pubitemid 29383642)
50. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986;320:584-8. (Pubitemid 16039134)
51. Lee YW, Kim PH, Lee WH, Hirani AA. Interleukin-4, oxidative stress, vascular inflammation and atherosclerosis. Biomol Ther (Seoul) 2010;18:135-44.
52. Brunetti ND, Pepe M, Munno I, Tiecco F, Quagliara D, De Gennaro L, et al. Th2-dependent cytokine release in patients treated with coronary angioplasty. Coron Artery Dis 2008;19:133-7. (Pubitemid 351555965)
53. Ransone LJ, Verma IM. Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol 1990;6:539-57.
54. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4: E131-6. (Pubitemid 34521026)
55. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010;1802:396-405.
56. Lee BW, Chun SW, Kim SH, Lee Y, Kang ES, Cha BS, et al. Lithospermic acid B protects beta-cells from cytokine-induced apoptosis by alleviating apoptotic pathways and activating anti-apoptotic pathways of Nrf2-HO-1 and Sirt1. Toxicol Appl Pharmacol 2011;252:47-54.
57. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002;2:725-34.
58. Yanagisawa K, Tago K, Hayakawa M, Ohki M, Iwahana H, Tominaga S. A novel splice variant of mouse interleukin-1-receptor-associated kinase-1 (IRAK-1) activates nuclear factor-kappaB (NF-kappaB) and c-Jun N-terminal kinase (JNK). Biochem J 2003;370:159-66. (Pubitemid 36259428)
59. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004;24:7806-19. (Pubitemid 39121503)
60. Liu Y, Guo YL, Zhou SJ, Liu F, Du FJ, Zheng XJ, et al. CREB is a positive transcriptional regulator of gamma interferon in latent but not active tuberculosis infections. Clin Vaccine Immunol 2010;17:1377-80.
61. Chow CW, Rincon M, Davis RJ. Requirement for transcription factor NFAT in interleukin-2 expression. Mol Cell Biol 1999;19:2300-7. (Pubitemid 29098287)
62. Barbulescu K, Becker C, Schlaak JF, Schmitt E, Meyer zum Buschenfelde KH, Neurath MF. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol 1998;160:3642-7. (Pubitemid 28176063)
63. Kim SH, Choi M, Lee Y, Kim YO, Ahn DS, Kim YH, et al. Natural therapeutic magnesium lithospermate B potently protects the endothelium from hyperglycaemia-induced dysfunction. Cardiovasc Res 2010;87:713-22.
64. Mesaik MA, Jabeen A, Halim SA, Begum A, Khalid AS, Asif M, et al. In silico and in vitro immunomodulatory studies on compounds of Lindelofia stylosa. Chem Biol Drug Des 2012;79:290-9.
65. Choudhary MI, Begum A, Abbaskhan A, Ajaz A, Shafique ur R, Atta ur R. Phenyl polypropanoids from Lindelofia stylosa. Chem Pharm Bull (Tokyo) 2005;53: 1469-71. (Pubitemid 41634220)
66. Rahman I. Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. Biochem Pharmacol 2002;64:935-42. (Pubitemid 35232267)
67. Mariappan N, Elks CM, Sriramula S, Guggilam A, Liu Z, Borkhsenious O, et al. NFkappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res 2010;85:473-83.
68. Zhao H, Jin S, Fan F, Fan W, Tong T, Zhan Q. Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res 2000;60:6276-80.
69. Sarkar SA, Kutlu B, Velmurugan K, Kizaka-Kondoh S, Lee CE, Wong R, et al. Cytokine-mediated induction of anti-apoptotic genes that are linked to nuclear factor kappa-B (NF-kappaB) signalling in human islets and in a mouse beta cell line. Diabetologia 2009;52:1092-101.
70. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
71. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 1996;271:31929-36. (Pubitemid 26422216)
72. +-ATPase inhibitors. Acta Pharmacol Sin 2011;32:141-51.